Gardner Syndrome Treatment Global Market 2024 - Latest Research, Industry Insights, Emerging Opportunities And Future Outlook By 2033

 

Overview and Scope

Gardner syndrome refers to a type of familial adenomatous polyposis (FAP), that causes multiple colon polyps (growths) and various types of cancerous or noncancerous tumors. Gardner syndrome treatment uses close monitoring of the polyps with lower GI tract endoscopy which helps limit the growth of colon polyps.

 

Sizing and Forecast

The gardner syndrome treatment market size has grown steadily in recent years. It will grow from $18.38 billion in 2023 to $19.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%.  The  growth in the historic period can be attributed to advancements in medical research, government regulations, increasing prevalence of gardner syndrome, market competition, healthcare infrastructure.

 

The gardner syndrome treatment market size is expected to see steady growth in the next few years. It will grow to $23.36 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%.  The growth in the forecast period can be attributed to innovations in treatment, market trends, global economic factors, patient preferences, pricing and reimbursement policies. Major trends in the forecast period include precision medicine advancements, immunotherapy breakthroughs, gene therapy innovation, diagnostic technologies, collaborative research initiatives.

 

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/gardner-syndrome-treatment-global-market-report

 

Segmentation & Regional Insights

The gardner syndrome treatment market covered in this report is segmented –

1) By Cancer Type: Dilated Cardiomyopathy, Skeletal Myopathy, Neutropenia, Other Cancer Types

2) By Therapeutics Type: NonSteroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 Inhibitor

3) By Application: Hospitals, Specialty Clinics, Other Applications

 

North America was the largest region in the gardner syndrome treatment market in 2023. The regions covered in the gardner syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

 

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9413&type=smp

 

Major Driver Impacting Market Growth

Rising cases of colon cancer is expected to propel the growth of the gardner syndrome treatment market going forward. Colon cancer refers to a type of cancer that begins in the large intestine. The colon is the last part of the digestive tract. Gardner syndrome treatment is used in colon cancer to prevent cancer by removing polyps during a colonoscopy as well as to prevent it through chemotherapy. For instance, in May 2022, according to the American Society of Clinical Oncology (ASCO), a US-based professional physicians’ organization, there were over 1.5 million colon cancer survivors in the USA in 2022, and it's expected to increase in the future. In addition to the 5-year survival rate, it increased by 65 percent where 51,030 adults in the USA were diagnosed with colon cancer in 2022. Therefore, rising cases of colon cancer are driving the growth of the Gardner syndrome treatment market.

 

Key Industry Players

Major companies operating in the gardner syndrome treatment market are launching new products to sustain their position in the market. For instance, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company launched Fruzaqla (fruquintinib), approved by Food and Drug Administration (FDA), a US-based federal government agency. Fruzaqla (fruquintinib) is a targeted therapy approved for the treatment of metastatic colorectal cancer (mCRC) in adults. Fruzaqla (fruquintinib) the first drug that targets all three subtypes of the vascular endothelial growth factor (VEGF) receptor kinases. Patients with Gardner syndrome are at a greater risk for developing colorectal cancer that is treated with Fruzaqla (fruquintinib).

 

The gardner syndrome treatment market report table of contents includes:

1. Executive Summary

2. Gardner Syndrome Treatment Market Characteristics

3. Gardner Syndrome Treatment Market Trends And Strategies

4. Gardner Syndrome Treatment Market - Macro Economic Scenario

5. Global Gardner Syndrome Treatment Market Size and Growth

................................

31. Global Gardner Syndrome Treatment Market Competitive Benchmarking

32. Global Gardner Syndrome Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Gardner Syndrome Treatment Market

34. Gardner Syndrome Treatment Market Future Outlook and Potential Analysis

35. Appendix

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info 

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model